Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

People living with Moderate-to-Severe COPD Prefer Improvement of Daily Symptoms Over the Improvement of Exacerbations: A Multi-Country Patient Preference Study

Nigel S. Cook, Gerard J. Criner, Pierre-Régis Burgel, Katie Mycock, Tom Gardner, Phil Mellor, Pam Hallworth, Kate Sully, Sophi Tatlock, Beyza Klein, Byron Jones, Olivier Le Rouzic, Kip Adams, Kirsten Phillips, Mike McKevitt, Kazuko Toyama, Florian S. Gutzwiller
ERJ Open Research 2022; DOI: 10.1183/23120541.00686-2021
Nigel S. Cook
1Novartis Pharma AG, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard J. Criner
2Temple University, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Régis Burgel
3Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
4Université de Paris and Institut Cochin, Inserm U1016, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pierre-Régis Burgel
Katie Mycock
5Adelphi Real World, Cheshire, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Gardner
6Adelphi Research, Cheshire, UK
14Employed by Adelphi when the study was conducted
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phil Mellor
6Adelphi Research, Cheshire, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pam Hallworth
6Adelphi Research, Cheshire, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Sully
7Adelphi Values, Cheshire, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophi Tatlock
7Adelphi Values, Cheshire, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beyza Klein
1Novartis Pharma AG, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Byron Jones
1Novartis Pharma AG, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Le Rouzic
8La Fondation du Souffle, Paris, France
9Univ. Lille, CHU Lille, Inserm U1019, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kip Adams
10COPD Foundation, Miami, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsten Phillips
11Lung Foundation, Australia, Brisbane, Queensland, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike McKevitt
12British Lung Foundation, England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuko Toyama
13J-Breath, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian S. Gutzwiller
1Novartis Pharma AG, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florian S. Gutzwiller
  • For correspondence: florian.gutzwiller@novartis.com
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction This patient preference study (PPS) sought to quantify the preferences of people living with chronic obstructive pulmonary disease (COPD) regarding symptom improvement in the United Kingdom, United States, France, Australia, and Japan.

Methods Inclusion criteria: People living with COPD aged 40 years or older who experienced ≥1 exacerbations in the previous year with daily symptoms of cough and excess mucus production. Study design: (I). development of an attributes and levels (A&L) grid through qualitative patient interviews; (II). implementation of the main online quantitative survey which included a discrete choice experiment (DCE) to allow assessment of attributes and levels using hypothetical health state profiles. Preference weights (utilities) were derived from the DCE using Hierarchical Bayesian analysis. A preference simulator was developed which enabled different health state scenarios to be evaluated based on the predicted patient preferences.

Results 1050 people living with moderate-to-severe COPD completed the survey. All attributes were considered important when patients determined their preferences in the DCE. In a health-state preference simulation, two hypothetical health states (comprising of attribute levels) with qualitatively equivalent improvements in A) cough and mucus and B) shortness of breath (SOB) resulted in a clear preference for cough and mucus-improved profile. When comparing two profiles with C) daily symptoms improved and D) exacerbations improved, there was a clear preference for the daily symptoms improved profile.

Conclusions People living with moderate-to-severe COPD prefer to reduce cough and mucus production together over improvement of SOB and would prefer to reduce combined daily symptoms over an improvement in exacerbations.

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: Nigel S. Cook, Beyza Klein, Byron Jones and Florian S. Gutzwiller are Novartis employees and hold shares in Novartis. Katie Mycock, Phil Mellor, Pam Hallworth, Kate Sully and Sophi Tatlock are Adelphi employees; Tom Gardner was employee of Adelphi when the study was conducted and Adelphi received payment for conducting the study. Pierre-Régis Burgel has received a consultancy fee from Novartis for his support throughout this COPD patient preferences project. He received personal fees (advisory boards, lecturing) from Astra-Zeneca, Chiesi, GSK, Insmed, Novartis, Pfizer, Teva, Vertex and Zambon and research grants from GSK and Vertex. Gerard J. Criner received a consultancy fee from Novartis for his support throughout this COPD patient preferences project. He received personal fees (advisory boards, lecturing) from Glaxo Smith Kline, Astra Zeneca, Chiesi, Sanofi, Olympus, Broncus, Pulmonx, Aerwave, EOLO, Boehringer Ingerlheim. Olivier Le Rouzic received personal fees (advisory boards, lecturing) from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis. All five patient groups from five countries (British Lung Foundation, UK; COPD Foundation, US; La Fondation du Soufflé, France; Lung Foundation Australia, and J-Breath, Japan) each received a consultancy fee at fair market value as compensation for their services throughout this project.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received December 24, 2021.
  • Accepted April 1, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

PreviousNext
Back to top
Vol 8 Issue 2 Table of Contents
ERJ Open Research: 8 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
People living with Moderate-to-Severe COPD Prefer Improvement of Daily Symptoms Over the Improvement of Exacerbations: A Multi-Country Patient Preference Study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
People living with Moderate-to-Severe COPD Prefer Improvement of Daily Symptoms Over the Improvement of Exacerbations: A Multi-Country Patient Preference Study
Nigel S. Cook, Gerard J. Criner, Pierre-Régis Burgel, Katie Mycock, Tom Gardner, Phil Mellor, Pam Hallworth, Kate Sully, Sophi Tatlock, Beyza Klein, Byron Jones, Olivier Le Rouzic, Kip Adams, Kirsten Phillips, Mike McKevitt, Kazuko Toyama, Florian S. Gutzwiller
ERJ Open Research Jan 2022, 00686-2021; DOI: 10.1183/23120541.00686-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
People living with Moderate-to-Severe COPD Prefer Improvement of Daily Symptoms Over the Improvement of Exacerbations: A Multi-Country Patient Preference Study
Nigel S. Cook, Gerard J. Criner, Pierre-Régis Burgel, Katie Mycock, Tom Gardner, Phil Mellor, Pam Hallworth, Kate Sully, Sophi Tatlock, Beyza Klein, Byron Jones, Olivier Le Rouzic, Kip Adams, Kirsten Phillips, Mike McKevitt, Kazuko Toyama, Florian S. Gutzwiller
ERJ Open Research Jan 2022, 00686-2021; DOI: 10.1183/23120541.00686-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Assessment for residual disease after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension
  • Acoustic surveillance of cough for detecting respiratory disease using artificial intelligence
  • “The whole of humanity has lungs, doesn't it, we are not all the same sort of people”. Patient preferences and choices for an online, self-guided chronic breathlessness supportive intervention (SELF-BREATHE)
Show more Original research article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2022 by the European Respiratory Society